DOCSLIB.ORG

Enabling the P450 Complement of Beauveria Bassiana and Rhodococcus Jostii for Biocatalysis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Enabling the P450 Complement of Beauveria Bassiana and Rhodococcus Jostii for Biocatalysis Enabling the P450 complement of Beauveria bassiana and Rhodococcus jostii for biocatalysis Claudia Spandolf PhD University of York Chemistry October 2015 I II Abstract Enzyme discovery today is proceeding at an enormous pace due to ever-growing technology development. As a result of this, more than 21000 cytochrome P450s have been identified in all kingdoms of life to date, making a wide range of enzyme resources with outstanding potential for biocatalytical implementation available. P450s from filamentous fungi, such as Beauveria bassiana, represent particularly compelling targets for the discovery of novel enzymes as these organisms have a long history of application in industrial hydroxylation reactions, many of which are believed to be P450-dependent. In addition, the genome sequence of B. bassiana has recently been completed revealing 83 putative P450s. In order to uncover new cytochrome P450-based biocatalysts from the fungus Beauveria bassiana extensive bioinformatics analysis of the Beauveria CYPome were performed. As a result 7 genes encoding for heme domains with possible alkane hydroxylase function and one encoding a naturally fused P450 with homology to P450foxy from Fusarium oxysporum could be identified for subsequent cloning, heterologous expression and characterization. Different expression hosts as well as various expression conditions have been investigated. Despite our efforts, delivery of active biocatalysts could not be realized. However, empirical data acquired in this project will be of value for future studies of fungal P450s. In addition, 23 cytochrome P450 heme domains from Rhodococcus jostii fused to the P450 reductase domain (RhfRED) of cytochrome P450Rhf from Rhodococcus sp. NCIMB 9784 have been investigated in a further strand of this work and provided a screening platform that could be applied for industrial purposes. III IV Table of Contents Abstract ..........................................................................................................III Table of Contents ........................................................................................... V List of Figures ................................................................................................ IX List of Tables .............................................................................................. XIII Acknowledgements ...................................................................................... XV Author’s Declaration ................................................................................. XVI 1. Introduction ................................................................................................. 1 1.1 Cytochrome P450 ............................................................................................................ 1 1.1.1 Discovery and Nomenclature ................................................................................... 1 1.1.2 Structure and Classes ............................................................................................... 5 1.1.3 Catalytic Reaction Mechanism .............................................................................. 12 1.1.4 Evolution and Catalysed Reactions ....................................................................... 16 1.1.5 Applications ........................................................................................................... 18 1.1.5.1 Potential and Limitations of P450s in biocatalysis .................................................................... 18 1.1.5.2 Commercial applications ........................................................................................................... 21 1.1.5.3 Medicine .................................................................................................................................... 28 1.1.5.4 Bioremediation .......................................................................................................................... 29 1.1.6 The fungal Kingdom .............................................................................................. 31 1.1.6.1 Fungi – the double-edged sword ................................................................................................ 31 1.1.6.2 Fungal P450 ............................................................................................................................... 33 1.2 Beauveria bassiana ....................................................................................................... 35 1.3 Rhodococcus jostii ........................................................................................................ 37 1.4 Project Aim ................................................................................................................... 38 2. General Material and Methods ................................................................ 39 2.1 Chemicals ...................................................................................................................... 39 2.2 Strains and Plasmids ..................................................................................................... 39 2.2.1 Escherichia coli strains .......................................................................................... 39 2.2.2 Yeast strains ........................................................................................................... 40 2.2.3 Plasmids ................................................................................................................. 40 2.3 Media ............................................................................................................................ 42 2.3.1 Escherichia coli ..................................................................................................... 42 2.3.2 Yeast ...................................................................................................................... 43 2.3.3 Supplements ........................................................................................................... 44 V 2.4 Glycerol stocks ............................................................................................................. 44 2.5 Working with nucleic acids .......................................................................................... 45 2.5.1 Enzymatic restriction of DNA ............................................................................... 45 2.5.2 Plasmid DNA preparation ..................................................................................... 45 2.5.3 Purification of DNA fragments ............................................................................. 45 2.5.4 Agarose gel electrophoresis ................................................................................... 46 2.5.5 In vitro-Amplification of DNA by PCR ................................................................ 46 2.5.6 Ligation independent cloning method ................................................................... 47 2.5.7 In Fusion cloning ................................................................................................... 49 2.6 Preparation of recombinant microorganisms ................................................................ 51 2.6.1 Preparation of CaCl2-competent E. coli-cells ........................................................ 51 2.6.2 Plasmid transformation into BL21 (DE3) and Rosetta2 (DE3) competent E. coli cells 52 2.6.3 Plasmid transformation into NovaBlue competent E. coli cells ............................ 52 2.6.4 Plasmid transformation into Saccharomyces cerevisiae WAT11 ......................... 52 2.7 Working with Proteins .................................................................................................. 53 2.7.1 Cell growth and protein expression ....................................................................... 53 2.7.1.1 Small scale expression test ........................................................................................................ 54 2.7.1.2 Scaled up protein expression ..................................................................................................... 54 2.7.2 Protein purification ................................................................................................ 54 2.7.3 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) ....... 55 2.7.4 Western blot ........................................................................................................... 57 2.7.4.1 Western blot set up and protein transfer .................................................................................... 57 2.7.4.2 Immunoprecipitation .................................................................................................................. 58 3. Selection of Beauveria bassiana P450 targets .......................................... 60 3.1 In situ analysis of CYPome .......................................................................................... 60 3.2 Phylogenetic tree .......................................................................................................... 64 3.3 Discussion ..................................................................................................................... 65 4. Construction of a library of B. bassiana P450 genes and their expression in E.coli ........................................................................................ 69 4.1 Materials and Methods ................................................................................................
Load more

Recommended publications
  • NIH Public Access Author Manuscript Pharmacogenet Genomics
    NIH Public Access Author Manuscript Pharmacogenet Genomics. Author manuscript; available in PMC 2013 February 01. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Pharmacogenet Genomics. 2012 February ; 22(2): 159–165. doi:10.1097/FPC.0b013e32834d4962. PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19 Stuart A. Scotta, Katrin Sangkuhlc, Alan R. Shuldinere,f, Jean-Sébastien Hulotb,g, Caroline F. Thornc, Russ B. Altmanc,d, and Teri E. Kleinc aDepartment of Genetics and Genomic Sciences bCardiovascular Research Center, Mount Sinai School of Medicine, New York, New York cDepartments of Genetics dBioengineering, Stanford University, Stanford, California eDivision of Endocrinology, Diabetes and Nutrition, University of Maryland School of Medicine fGeriatric Research and Education Clinical Center, Veterans Administration Medical Center, Baltimore, Maryland, USA gDepartment of Pharmacology, Université Pierre et Marie Curie-Paris 6, INSERM UMR S 956, Pitié-Salpêtrière University Hospital, Paris, France Abstract This PharmGKB summary briefly discusses the CYP2C19 gene and current understanding of its function, regulation, and pharmacogenomic relevance. Keywords antidepressants; clopidogrel; CYP2C19*17; CYP2C19*2; CYP2C19; proton pump inhibitors; rs4244285 Introduction The cytochrome P450, family 2, subfamily C, polypeptide 19 (CYP2C19) gene is located within a cluster of cytochrome P450 genes (centromere-CYP2C18-CYP2C19-CYP2C9- CYP2C8-telomere) on chromosome 10q23.33. The CYP2C19 enzyme contributes to the metabolism of a large number of clinically relevant drugs and drug classes such as antidepressants [1], benzodiazepines [2], mephenytoin [3], proton pump inhibitors (PPIs) [4], and the antiplatelet prodrug clopidogrel [5]. Similar to other CYP450 genes, inherited genetic variation in CYP2C19 and its variable hepatic expression contributes to the interindividual phenotypic variability in CYP2C19 substrate metabolism.
    [Show full text]
  • Identification and Characterization of CYP2C18 in the Cynomolgus Macaque (Macaca Fascicularis)
    NOTE Toxicology Identification and Characterization of CYP2C18 in the Cynomolgus Macaque (Macaca fascicularis) Yasuhiro UNO1)*, Kiyomi MATSUNO1), Chika NAKAMURA1), Masahiro UTOH1) and Hiroshi YAMAZAKI2) 1)Pharmacokinetics and Bioanalysis Center (PBC), Shin Nippon Biomedical Laboratories (SNBL), Kainan, Wakayama 642–0017 and 2)Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Machida, Tokyo 194–8543, Japan (Received 3 August 2009/Accepted 15 September 2009/Published online in J-STAGE 25 November 2009) ABSTRACT. The macaque is widely used for investigation of drug metabolism due to its evolutionary closeness to the human. However, the genetic backgrounds of drug-metabolizing enzymes have not been fully investigated; therefore, identification and characterization of drug-metabolizing enzyme genes are important for understanding drug metabolism in this species. In this study, we isolated and char- acterized a novel cytochrome P450 2C18 (CYP2C18) cDNA in cynomolgus macaques. This cDNA was highly homologous (96%) to human CYP2C18 cDNA. Cynomolgus CYP2C18 was preferentially expressed in the liver and kidney. Moreover, a metabolic assay using cynomolgus CYP2C18 protein heterologously expressed in Escherichia coli revealed its activity toward S-mephenytoin 4’-hydrox- ylation. These results suggest that cynomolgus CYP2C18 could function as a drug-metabolizing enzyme in the liver. KEY WORDS: cloning, CYP2C18, cytochrome P450, liver, monkey. J. Vet. Med. Sci. 72(2): 225–228, 2010 Cytochrome P450 (CYP) is a superfamily of some of the Such species differences also could be explained by func- most important drug-metabolizing enzymes and consists of tional disparity of the orthologous CYPs between the two a large number of subfamilies [14]. In humans, the CYP2C species, such as, if an ortholog to human CYP with low (or subfamilies contain important enzymes that metabolize no) expression and drug-metabolizing activity, for example approximately 20% of all prescribed drugs [3].
    [Show full text]
  • Synonymous Single Nucleotide Polymorphisms in Human Cytochrome
    DMD Fast Forward. Published on February 9, 2009 as doi:10.1124/dmd.108.026047 DMD #26047 TITLE PAGE: A BIOINFORMATICS APPROACH FOR THE PHENOTYPE PREDICTION OF NON- SYNONYMOUS SINGLE NUCLEOTIDE POLYMORPHISMS IN HUMAN CYTOCHROME P450S LIN-LIN WANG, YONG LI, SHU-FENG ZHOU Department of Nutrition and Food Hygiene, School of Public Health, Peking University, Beijing 100191, P. R. China (LL Wang & Y Li) Discipline of Chinese Medicine, School of Health Sciences, RMIT University, Bundoora, Victoria 3083, Australia (LL Wang & SF Zhou). 1 Copyright 2009 by the American Society for Pharmacology and Experimental Therapeutics. DMD #26047 RUNNING TITLE PAGE: a) Running title: Prediction of phenotype of human CYPs. b) Author for correspondence: A/Prof. Shu-Feng Zhou, MD, PhD Discipline of Chinese Medicine, School of Health Sciences, RMIT University, WHO Collaborating Center for Traditional Medicine, Bundoora, Victoria 3083, Australia. Tel: + 61 3 9925 7794; fax: +61 3 9925 7178. Email: [email protected] c) Number of text pages: 21 Number of tables: 10 Number of figures: 2 Number of references: 40 Number of words in Abstract: 249 Number of words in Introduction: 749 Number of words in Discussion: 1459 d) Non-standard abbreviations: CYP, cytochrome P450; nsSNP, non-synonymous single nucleotide polymorphism. 2 DMD #26047 ABSTRACT Non-synonymous single nucleotide polymorphisms (nsSNPs) in coding regions that can lead to amino acid changes may cause alteration of protein function and account for susceptivity to disease. Identification of deleterious nsSNPs from tolerant nsSNPs is important for characterizing the genetic basis of human disease, assessing individual susceptibility to disease, understanding the pathogenesis of disease, identifying molecular targets for drug treatment and conducting individualized pharmacotherapy.
    [Show full text]
  • Caffeine Metabolism and Cytochrome P450 Enzyme Mrna Expression
    Caffeine metabolism and Cytochrome P450 enzyme mRNA expression levels of genetically diverse inbred mouse strains Neal Addicott - CSU East Bay, Michael Malfatti - Lawrence Livermore National Laboratory, Gabriela G. Loots - Lawrence Livermore National Laboratory Metabolic pathways for caffeine 4. Results 1. Introduction (in mice - human overlaps underlined) Metabolites 30 minutes after dose Caffeine is broken down in humans by several enzymes from the Cytochrome Caffeine (1,3,7 - trimethylxanthine) O CH3 (n=6 per strain) CH3 6 N Paraxanthine/Caffeine N 7 Theophylline/Caffeine *Theobromine/Caffeine P450 (CYP) superclass of enzymes. These CYP enzymes are important in Theophylline 1 5 0.06 0.06 0.06 8 (7-N-demethylization) (1,3 - dimethylxanthine) 2 4 9 3 O N 0.05 0.05 0.05 activating or eliminating many medications. The evaluation of caffeine O H N 1,3,7 - trimethyluricacid CH 3 O CH3 N CH eine Peak Area Peak eine eine Peak Area eine Cyp1a2 3 CH 0.04 Area Peak eine 0.04 0.04 f f N f metabolites in a patient has been proposed as a means of estimating the activity 1 7 3 (3-N-demethylization) N Cyp3a4 N1 7 (8-hydrolyzation) 8 OH 0.03 0.03 0.03 of some CYP enzymes, contributing to genetics-based personalized medicine. O 3 N N Cyp1a2 3 O N Paraxanthine (1-N-demethylization) N 0.02 0.02 0.02 CH3 (1,7 - dimethylxanthine) CH3 O CH3 0.01 0.01 0.01 CH3 Theophylline Peak Area / Ca Peak Theophylline Paraxanthine Peak Area / Ca The frequency and distribution of polymorphisms in inbred strains of mice N Area / Ca Peak Theobromine 7 paraxanthine peak area /caffeine peak area /caffeine paraxanthine peak area theophylline peak area /caffeine peak area /caffeine theophylline peak area N1 Theobromine 0 0 peak area /caffeine peak area theobromine 0 0 C57BL/6JC57BL BALB/cJBALB CBA/JCBA/J DBA/2JDBA/2J .
    [Show full text]
  • © Central University of Technology, Free State DECLARATION
    © Central University of Technology, Free State DECLARATION DECLARATION I, MOHAMMAD PARVEZ (INDIAN PASSPORT NUMBER ), hereby certify that the dissertation submitted by me for the degree DOCTOR OF HEALTH SCIENCES IN BIOMEDICAL TECHNOLOGY, is my own independent work; and complies with the Code of Academic Integrity, as well as other relevant policies, procedures, rules and regulations of the Central University of Technology (Free State). I hereby declare, that this research project has not been previously submitted before to any university or faculty for the attainment of any qualification. I further waive copyright of the dissertation in favour of the Central University of Technology (Free State). I also state that expression vector modified/generated in this study is in collaboration with my colleagues, Mr HANS DENIS BAMAL (student number: ) and Ms IPELENG KOPANO ROSINAH KGOSIEMANG (student number: ). MOHAMMAD PARVEZ DATE II | P a g e © Central University of Technology, Free State © Central University of Technology, Free State ACKNOWLEDGEMENT ACKNOWLEDGEMENTS This thesis would have remained a dream, had it not been for my supervisor, Prof Khajamohiddin Syed, who continuously supported me during my doctoral study. I would like to extend my gratitude to him, for his patience, motivation, enthusiasm, and immense knowledge in P450 research. I would also like to thank him for giving me the opportunity to attend national and international scientific conferences. He has shown great faith and trust in me throughout my studies and without such attributes I may not be where I am now. I would also like to thank Prof Samson Sitheni Mashele for his support, and always listening to our concerns.
    [Show full text]
  • Regulation of Human CYP2C18 and CYP2C19 in Transgenic Mice: Influence of Castration, Testosterone, and Growth Hormone□S
    Supplemental Material can be found at: http://dmd.aspetjournals.org/cgi/content/full/dmd.109.026963/DC1 0090-9556/09/3707-1505–1512$20.00 DRUG METABOLISM AND DISPOSITION Vol. 37, No. 7 Copyright © 2009 by The American Society for Pharmacology and Experimental Therapeutics 26963/3478494 DMD 37:1505–1512, 2009 Printed in U.S.A. Regulation of Human CYP2C18 and CYP2C19 in Transgenic Mice: Influence of Castration, Testosterone, and Growth Hormone□S Susanne Lo¨ fgren, R. Michael Baldwin,1 Margareta Carlero¨ s, Ylva Terelius, Ronny Fransson-Steen, Jessica Mwinyi, David J. Waxman, and Magnus Ingelman-Sundberg Safety Assessment, AstraZeneca Research and Development, So¨ derta¨ lje, Sweden (S.L., R.F.-S.); Department of Physiology and Pharmacology, Section of Pharmacokinetics, Karolinska Institutet, Stockholm, Sweden (R.M.B., M.C., J.M., M.I.-S.); Drug Metabolism and Pharmacokinetics and Bioanalysis, Bioscience, Medivir AB, Huddinge, Sweden (Y.T.); and Division of Cell and Molecular Biology, Department of Biology, Boston University, Boston, Massachusetts (D.J.W.) Received January 29, 2009; accepted March 26, 2009 ABSTRACT: Downloaded from The hormonal regulation of human CYP2C18 and CYP2C19, which GH treatment of transgenic males for 7 days suppressed hepatic are expressed in a male-specific manner in liver and kidney in a expression of CYP2C19 (>90% decrease) and CYP2C18 (ϳ50% mouse transgenic model, was examined. The influence of prepu- decrease) but had minimal effect on the expression of these genes bertal castration in male mice and testosterone treatment of fe- in kidney, brain, or small intestine. Under these conditions, contin- male mice was investigated, as was the effect of continuous ad- uous GH induced all four female-specific mouse liver Cyp2c genes dmd.aspetjournals.org ministration of growth hormone (GH) to transgenic males.
    [Show full text]
  • Biosynthesis of New Alpha-Bisabolol Derivatives Through a Synthetic Biology Approach Arthur Sarrade-Loucheur
    Biosynthesis of new alpha-bisabolol derivatives through a synthetic biology approach Arthur Sarrade-Loucheur To cite this version: Arthur Sarrade-Loucheur. Biosynthesis of new alpha-bisabolol derivatives through a synthetic biology approach. Biochemistry, Molecular Biology. INSA de Toulouse, 2020. English. NNT : 2020ISAT0003. tel-02976811 HAL Id: tel-02976811 https://tel.archives-ouvertes.fr/tel-02976811 Submitted on 23 Oct 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. THÈSE En vue de l’obtention du DOCTORAT DE L’UNIVERSITÉ DE TOULOUSE Délivré par l'Institut National des Sciences Appliquées de Toulouse Présentée et soutenue par Arthur SARRADE-LOUCHEUR Le 30 juin 2020 Biosynthèse de nouveaux dérivés de l'α-bisabolol par une approche de biologie synthèse Ecole doctorale : SEVAB - Sciences Ecologiques, Vétérinaires, Agronomiques et Bioingenieries Spécialité : Ingénieries microbienne et enzymatique Unité de recherche : TBI - Toulouse Biotechnology Institute, Bio & Chemical Engineering Thèse dirigée par Gilles TRUAN et Magali REMAUD-SIMEON Jury
    [Show full text]
  • Evaluation of Yarrowia Lipolytica As a Host For
    EVALUATION OF YARROWIA LIPOLYTICA AS A HOST FOR CYTOCHROME P450 MONOOXYGENASE EXPRESSION By GEORGE OGELLO OBIERO B.Sc. (U.O.N); M.Sc. (U.B) Submitted in fulfilment of the requirements for the degree PHILOSOPHIAE DOCTOR In the Faculty of Natural and Agricultural Sciences, Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State, Bloemfontein, South Africa June, 2006 Promoter: Prof. M.S. Smit "It's not that I'm so smart, it's just that I stay with problems longer." Albert Einstein (1879-1955) I This thesis is dedicated to my late mother, Mrs. Beldine Obiero and my dad, Mr. Gabriel Obiero whose unwavering support and encouragement has been my pillar of strength. II ACKNOWLEDGEMENTS I would like to express my sincere gratitude toward the following people: Prof. M.S. Smit for her invaluable guidance, patience and constructive criticism during the course of the study. Thanks for the patience and determination throughout this project. Mr. P.J. Botes for his technical assistance with the chemical analyses. Dr. E. setati for her valuable and motivating discussions. All my colleagues in Biotransformation Research Group. Fellow students and staff in the Department of Microbial, Biochemical and Food Biotechnology, University of Free State My family and friends for being there for me throughout the study and for their much needed words of encouragement and support. National Research Foundation (NRF) for the financial support of this project. The Heavenly Father without whom this work would not have been successful. III TABLE OF CONTENTS CHAPTER 1: INTRODUCTION 1. Introduction............................................................................................................ 1 1.1.
    [Show full text]
  • CYP2C9 Polymorphisms in Human Tumors
    ANTICANCER RESEARCH 26: 299-306 (2006) CYP2C9 Polymorphisms in Human Tumors HEIKE KNÜPFER1*, DIRK STANITZ2 and RAINER PREISS1 1University of Leipzig, Department of Clinical Pharmacology, Leipzig; 2Department of Internal Medicine, Hospital of the Paul-Gerhardt-Stiftung, Lutherstadt Wittenberg, Germany Abstract. The oxazaphosphorines cyclophosphamide (CP) derivative (phosphoramide mustard or ifosphoramide and ifosfamide (IF) are alkylating agents that require mustard) and acrolein. The mustard alkylates DNA and is bioactivation via cytochrome (CYP) P450 isoenzymes considered to be the therapeutically significant cytotoxic including CYP2C9 enzymes. The present study investigated metabolite. CYP2C9 in regard to its allelic variants in 23 tumor samples Multiple human P450 enzymes are capable of activating (10 breast tumors, 1 breast tumor cell line, 5 brain tumors, 7 oxazaphosphorines, among them CYP3A (2-5) and CYP2C glioma cell lines) with restriction fragment length enzymes (6). Four CYP2C genes have been identified – polymorphism polymerase chain reaction (RFLP-PCR). The CYP2C8, CYP2C9, CYP2C18 and CYP2C19 (7). Of those, mutant alleles of CYP2C9 were residue 144 (Arg (*1)/Cys CYP2C9 is expressed at the highest concentration in human (*2)), residue 358 (Tyr/Cys), residue 359 (Ile/Leu (*3)) and liver (8). CYP2C9 catalyzes the oxidation of diverse xenobiotic residue 417 (Gly/Asp). The frequencies of the CYP2C9*1, chemicals, such as tolbutamide, warfarin, flurbiprofen, CYP2C9*2 and CYP2C9*3 alleles in the cancer samples phenytoin, hexobarbital, diclofenac (8, 9) and also the examined were found to be 0.848, 0.152 and 0.043, anticancer agents ifosfamide and cyclophosphamide (6). respectively. No sample revealed a mutation at residue 358 or The metabolic activation of the oxazaphosphorines is 417.
    [Show full text]
  • Targeting of Insect Epicuticular Lipids by the Entomopathogenic Fungus Beauveria Bassiana: Hydrocarbon Oxidation Within the Context of a Host-Pathogen Interaction
    ORIGINAL RESEARCH ARTICLE published: 15 February 2013 doi: 10.3389/fmicb.2013.00024 Targeting of insect epicuticular lipids by the entomopathogenic fungus Beauveria bassiana: hydrocarbon oxidation within the context of a host-pathogen interaction Nicolás Pedrini 1, Almudena Ortiz-Urquiza 2, Carla Huarte-Bonnet 1, Shizhu Zhang 2,3 and Nemat O. Keyhani 2* 1 Facultad de Ciencias Médicas, Instituto de Investigaciones Bioquímicas de La Plata (CCT La Plata CONICET-UNLP), La Plata, Argentina 2 Department of Microbiology and Cell Science, University of Florida, Gainesville, FL, USA 3 Jiangsu Key Laboratory for Microbes and Functional Genomics, Jiangsu Engineering and Technology Research Center for Microbiology, College of Life Sciences, Nanjing Normal University, Nanjing, China Edited by: Broad host range entomopathogenic fungi such as Beauveria bassiana attack insect hosts Rachel N. Austin, Bates College, via attachment to cuticular substrata and the production of enzymes for the degradation USA and penetration of insect cuticle. The outermost epicuticular layer consists of a complex Reviewed by: mixture of non-polar lipids including hydrocarbons, fatty acids, and wax esters. Long chain Rachel N. Austin, Bates College, USA hydrocarbons are major components of the outer waxy layer of diverse insect species, Alan A. DiSpirito, Ohio State where they serve to protect against desiccation and microbial parasites, and as recognition University, USA molecules or as a platform for semiochemicals. Insect pathogenic fungi have evolved *Correspondence: mechanisms for overcoming this barrier, likely with sets of lipid degrading enzymes with Nemat O. Keyhani, Department of overlapping substrate specificities. Alkanes and fatty acids are substrates for a specific Microbiology and Cell Science, University of Florida, Gainesville, subset of fungal cytochrome P450 monooxygenases involved in insect hydrocarbon FL 32611, USA.
    [Show full text]
  • Expression of CYP2S1 in Human Hepatic Stellate Cells
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector FEBS Letters 581 (2007) 781–786 Expression of CYP2S1 in human hepatic stellate cells Carylyn J. Mareka, Steven J. Tuckera, Matthew Korutha, Karen Wallacea,b, Matthew C. Wrighta,b,* a School of Medical Sciences, Institute of Medical Science, University of Aberdeen, Aberdeen, UK b Liver Faculty Research Group, School of Clinical and Laboratory Sciences, University of Newcastle, Newcastle, UK Received 22 November 2006; revised 16 January 2007; accepted 23 January 2007 Available online 2 February 2007 Edited by Laszlo Nagy the expression and accumulation of scarring extracellular Abstract Activated stellate cells are myofibroblast-like cells associated with the generation of fibrotic scaring in chronically fibrotic matrix protein [2]. It is currently thought an inhibition damaged liver. Gene chip analysis was performed on cultured fi- of fibrosis in liver diseases may be an effective approach to brotic stellate cells. Of the 51 human CYP genes known, 13 treating patients for which the cause is refractive to current CYP and 5 CYP reduction-related genes were detected with 4 treatments (e.g. in approx. 30% of hepatitis C infected CYPs (CYP1A1, CYP2E1, CY2S1 and CYP4F3) consistently patients) [2,3]. At present, there is no approved treatment for present in stellate cells isolated from three individuals. Quantita- fibrosis. tive RT-PCR indicated that CYP2S1 was a major expressed Inadvertent toxicity of drugs is often associated with a ‘‘met- CYP mRNA transcript. The presence of a CYP2A-related pro- abolic activation’’ by CYPs [1].
    [Show full text]
  • Early Pregnancy Maternal Progesterone Administration Alters Pituitary and Testis Function and Steroid Profile in Male Fetuses
    www.nature.com/scientificreports OPEN Early pregnancy maternal progesterone administration alters pituitary and testis function and steroid profle in male fetuses Katarzyna J. Siemienowicz1,2*, Yili Wang1, Magda Marečková1, Junko Nio‑Kobayashi1,3, Paul A. Fowler4, Mick T. Rae2 & W. Colin Duncan1 Maternal exposure to increased steroid hormones, including estrogens, androgens or glucocorticoids during pregnancy results in chronic conditions in ofspring that manifest in adulthood. Little is known about efects of progesterone administration in early pregnancy on fetal development. We hypothesised that maternal early pregnancy progesterone supplementation would increase fetal progesterone, afect progesterone target tissues in the developing fetal reproductive system and be metabolised to other bioactive steroids in the fetus. We investigated the efects of progesterone treatment during early pregnancy on maternal and fetal plasma progesterone concentrations, transcript abundance in the fetal pituitary and testes and circulating steroids, at day 75 gestation, using a clinically realistic ovine model. Endogenous progesterone concentrations were lower in male than female fetuses. Maternal progesterone administration increased male, but not female, fetal progesterone concentrations, also increasing circulating 11‑dehydrocorticosterone in male fetuses. Maternal progesterone administration altered fetal pituitary and testicular function in ovine male fetuses. This suggests that there may be fetal sex specifc efects of the use of progesterone in early pregnancy, and highlights that progesterone supplementation should be used only when there is clear evidence of efcacy and for as limited time as necessary. Fetal exposure to sex steroids has critical roles in sexual diferentiation and the programming of health and dis- ease in later life1. Exposure to endocrine disrupting compounds is linked to disease development in ofspring2.
    [Show full text]